The head of Biogen Idec says his company will recommend a stronger warning label for a multiple sclerosis drug it hopes to return to the market. James Mullen, Biogen's chief executive and president, told The Associated Press today that the company will recommend that regulators include a warning about Tysabri's link to a rare but often-fatal brain disease.
technorati tags: multiple sclerosis, tysabri
No comments:
Post a Comment